Compare Chubb Ltd (CB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs GSK plc — how do they compare? Chubb Ltd trades at $345.98 (market cap $134.28B), while GSK plc trades at $51.18 (market cap $101.55B). The key difference: Chubb Ltd is the larger of the two by market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| CB | GSK | |
|---|---|---|
Market Cap | $134.28B | $101.55B |
Sector | Financials | Health |
52-Week High | $361.17 | $61.18 |
52-Week Low | $265.99 | $36.20 |
Enterprise Value | $155.34B | $122.16B |
Dividend Yield | 1.18% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $354.74, up 1.99% today, with a bullish technical outlook supported by moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $6.82 versus $6.60 expected, highlight robust profitability with a net income margin of 18.46% and ROE of 16.2%. The company maintains disciplined capital deployment, with a recent $1.02 dividend declared for H1 2026.
The stock offers a compelling value with a P/E of 12.55 and consensus price target of $361.67, though near-term risks include catastrophe losses and softer commercial pricing. Long-term growth is supported by premium expansion and investment income, but investors should monitor underwriting margins and market volatility.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
